research
Our Pulmonary Hypertension Center
, , Filed in: PAH, Pulmonary HTN, Clinical Trials
Lexington Pulmonary and Critical Care has one of the most active Pulmonary Arterial Hypertension diagnosis and treatment centers in South Carolina. We see patients referred from cardiologists, pulmonologists, internists, rheumatologists, and other specialists for pulmonary hypertension and complete a full evaluation to determine if the disease exists, why it exists, and what the best treatment options are or the individual patient.
We also offer participation in several clinical trials to assure that our patients can receive the latest in State-of-the-art care right here in the Columbia/Lexington area that used to be available only at major medical centers.
As of today (July 23, 2011) we are actively following about 200 patients with known or suspected pulmonary hypertension.
We have the following number of patients on the various approved therapy for pulmonary hypertension:
Tracleer (bosentan) 22
Letairis (ambrisentan) 24
Revatio (sildenafil) 5
Adcirca (tadalafil) 15
Ventavis (iloprost) 5
Tyvaso (treprostinil) 6
We are currently recruiting patients for the following clinical trials related to treatment of pulmonary arterial hypertension:
COMPASS-2 study - This is a drug study sponsored by Actelion Pharmaceuticals testing the combination of sildenafil and bosentan for treatment of Pulmonary Arterial Hypertension.
For referrals call our office at 803-520-5100 or send email to delton@lexpcc.net.
We also offer participation in several clinical trials to assure that our patients can receive the latest in State-of-the-art care right here in the Columbia/Lexington area that used to be available only at major medical centers.
As of today (July 23, 2011) we are actively following about 200 patients with known or suspected pulmonary hypertension.
We have the following number of patients on the various approved therapy for pulmonary hypertension:
Tracleer (bosentan) 22
Letairis (ambrisentan) 24
Revatio (sildenafil) 5
Adcirca (tadalafil) 15
Ventavis (iloprost) 5
Tyvaso (treprostinil) 6
We are currently recruiting patients for the following clinical trials related to treatment of pulmonary arterial hypertension:
COMPASS-2 study - This is a drug study sponsored by Actelion Pharmaceuticals testing the combination of sildenafil and bosentan for treatment of Pulmonary Arterial Hypertension.
For referrals call our office at 803-520-5100 or send email to delton@lexpcc.net.